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and pra and post each apheresis session using routine laboratory assays. Features of 
calcified coronary plaque burden (Agatston Score, calcified plaque vol-ume, calcified 
plaque density) were measured using ECG- triggered fast CT at baseline and at the end 
of the study period. The effects of decreased blood lipoprotein exposure on coronary cal- 
cified plaque were evaluated. On average, total cholesterol, LDL- cholesterol, triglycer- 
ides and Lipoprotein (a) were substantially lowered as compared to baseline (52.9%, 
P<0.0G01 ; 64.5%, P<0.O001; 48.7%, P<0.004 and; 45.3%, P<0.05), respectively. In con- 
trast, mean HDL Cholesterol increased by 13.9% (P<0.07). Concomitantly the Agat-ston 
Score decreased by 26.1+14.3% (213.'~?.03, P<0.03), calcified plaque volume was 
reduced by 23.4±14.8% (186±199 ram3, P<0.03) and calcified plaque density increased 
by 17.2_+10.7% (40~32 HU, P<0.01). The increase of plaque density was correlated to 
the reduction of total cholesterol levels (r=0.73, P<0.04). 
Conclusion: Coronary calcified plaque volume decreases and mean calcified plaque den- 
sity increases during long term maximal lipid lowering intervention. This regression 
potentially depends on the extent of lipid lowering and can be tracked quantitatively by 
computed tomography. 
1107-88 Statin Therapy but Not Exercise Inhibits Rates of  
Progression of Coronary Calc i f icat ion 
Matthew J. Budoff, Nisha Agrawal, David S. Reiss, Tej Naik, Thuy Le, Kedisha Mayet, 
Harbor-UCLA Research and Education Institute, Torrance, California. 
Background: Coronary artery calcification (CAC) by Electron Beam Tornography (EBT) is 
linearly associated with atherosclerotic plaque burden. The influence of different thera- 
pies to influence EBT calcium progression has not been well described. 
Methods: The aim of this study was to determine the changes in CAC, under the influ- 
ence of several interventions, as measured by electron beam tomography in consecutive 
patients presenting in our laboratory for follow-up. To evaluate the rates of progression, 
we evaluated 555 patients (mean age 59 +/-9 years, 78% men). The interscan period 
was 3.0 +/- 1.6 years. EBT scores were calculated using the Agatston method. The 
results were reported in % EBT score change/year. Due to high variabilities in the very 
low scores, patients with baseline scores >10 were included. Multivariate analysis was 
used to assess the independent effects of different therapies or conditions. 
Results: Mean calcium score in this cohort was 257, and increased by 29.5 points per 
year. The mean rate of progression of the entire cohort was 18+/-7%. 241 patients were 
treated with statin therapy during the entire interscan period, with mean progression of 
13+/-11%. In the 89 patients with high cholesterol who were not taking therapy, the rate 
of progression was 29+/-12% per year. There was a significant difference between the 
rates of progression between the groups (p=0.005). This study demonstrated statin ther- 
apy to be a significant, independent predictor of the progression of coronary calcium 
(odds ratio [OR] 2.41; 95% confidence interval [CI], 1.29, 4.75). Patients reporting regular 
exercise (n=334) had a rate of progression of 16+/-8%, while persons reporting no exer- 
cise had progression rates of 19+/-9% per year (p=n.s.). No cardiovascular risk factors 
were related to progression of plaque in the multivariate model. 
Conclusion: Statin therapy, but not exercise, inhibited CAC progression. The prognostic 
significance of increasing CAC plaque remains to be determined. However, given the 
association of increased atherosclerosis with increased CAC, use of cholesterol-lowering 
therapy should be considered in patients with CAC to slow plaque progression. 
1107-89 Change in Calci f ied Plaque Burden in Relation to  
Aggressiveness of Treatment and Baseline LDL 
Cholesterol Levels 
Harvev S. Hecht, S Mitchell Harman, Heart and Vascular Institute, Mordstown, New 
Jersey, Kronos Research Institute, Phoenix, Arizona. 
To determine 1) whether or not progression of calcified plaque burden in the primary pre- 
vention population is significantly reduced by more aggressive LDLC lowering and 2) 
whether treatment will benefit pts with NCEP higher risk initial LDLC more than lower risk 
pts, 172 asymptomatic men (137) and women (35) without clinical CAD were evaluated 
by serial Electron Beam Tomography (EBT), before and 1.2±0.3 yrs after intitiation of 
lipid therapy. Statins were used in 163, niacin in 98, fibrates in 2, and statin+niacin in 85. 
Percent change/yr in EBT volume (V) and score (S) were compared in pts achieving final 
(F) LDLC80mg/dl and in pts with initial (I) LDLC >130 vs <130 mg/dl (Table). Conclu- 
sions: 1)After 1.2 yrs of treatment, there were no differences in calcified plaque burden 
progression in pts achieving LDLCS0 mg/dl; i.e. lower was not better, and plaque pro- 
gression was similar with initial LDLC<130 vs >130mg/dl; i.e. in pts defined as lower vs 
higher risk by NCEP. 2) A longer treatment period may be needed to produce differences 
between groups. 
Changes In EBT Calcium In Relation to Rlek (Initial LDLC) and Response to 
Treatment (Final LDLC) 
ABSTRACTS - Hypertension, Vascular Disease, and Prevention JACC March 6, 2002 
Final LDL F >80 F*80 pvalue Initial LDL 1>130 1"130 p value 
n 74 98 n 82 87 
I-LDLC 138±46 122±28 0.007 LDLC 156±31 104±21 <0.001 
I-EBT S 380±390 513±698 0.07 I-EBT S 453±501 592±829 0.16 
F-LDLC 99±18 64±11 <0.001 F-LDLC 85±23 73±19 <0.001 
I-EBT V 307±315 407±544 0.08 I-EBT V 353±381 468±646 0.17 
%changeS/yr 19.5±45.3 12.2±29.8 0.20 %changeS/yr 12.8±23.2 16.6±46.6 0.52 
%change V/yr 15.1±35.8 12.3±28.1 0.57 %changeV/yr 11.8±24.0 14.5±36.8 0.57 
1107-90 Comparison of Statin Versus Ststin+Niacin Treatment in 
Primary Prevention: Effect on Change in Calcified 
Plaque Burden 
Harvev S. Hecht. S Mitchell Harman, Heart and Vascular Institute, Morristown, New 
Jersey, Kronos Research Institute, Phoenix, Arizona. 
The effects on calcified plaque burden by Electron Beam Tomography (EBT) of statin 
therapy (ST) to lower LDLC and stalin+niacin therapy (ST+N) to treat combined LDLC 
and HDLC/Trig abnormalities were compared in 162 asymptomatic patients without clini- 
cal CAD. EBT score (S) and volume (V) were obtained before and after a mean of 1.25 
yrs of ST (n=78) or 1.18 yrs of ST+N (n=84) therapy. Except for HDLC in the S group, 
lipid and EBT values all changed significantly after treatment (Table), Final LDLC was 
lower in the ST+N group (p<.03) but final HDLC and Trig did not differ significantly. There 
were no significant differences between groups in the change in LDLC, but changes in 
HDLC (p<0.0001) and Trig (p<0.006) were greater in the ST+N group. There were no dif- 
ferences between ST and ST+N in % change in EBT-S/yr (13.4 vs 17.2, p=0.9) or % 
change in EBT-V/yr (11.2 vs 16.4, p=0.77). Conclusions: ST and ST+N therapies 1) 
addressed different lipid profiles and produced significantly improved lipid values, and 2) 
did not differ in terms of rates of calcified plaque progression after t .2 yrs of treatment. 
Changes In Lipid and EBT Values In Patients on Statln end Statln + Niacin 
Statin Stalin + Niacin 
Baseline Final p value Baseline Final p value 
LDLC 134±41 83±23 <0.001 129±30 73±18 <0.001 
HDLC 58±17 60±18 0.21 44±12 54±14 <0.001 
Trig 119±71 95±57 <0.001 170±121 109±63 <0.001 
EBT-S 449±698 507±825 0.004 484±486 552+563 <0.0001 
EBT-V 359±564 399±638 0.01 387±383 434±424 <0.001 
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1108-69 Regression of Echocardiographic Left Ventricular 
Hypertrophy in Relation to Resolution Versus 
Persistence of Electrocardiographic Strain After One 
Year of Antlhypertensive Therapy: The LIFE Study 
Peter M. Okin, Richard B. Devereux, Vittorio Palmieri, Jennifer E. Liu, Kristian Wachtell, 
Markku S. Nieminen, Sverker Jam, Lasse Oikarinen, Matti Viitasalo, Sverre E. Kjeldsen, 
Stevo Julius, Bjorn Dahlof, for the LIFE Study Investigators, Cornel/Medics~ Center, New 
York, New York. 
Background: Presence of the ECG strain pattern (ST depression and T-wave inversion 
in leads V5 and/or V6) at LIFE study baseline was associated with greater left ventricular 
mass index (LVMI) and a higher prevalence of LV hypertrophy (LVH). However, the rela- 
tion of resolution vs persistence of ECG strain to changes in LVM and LVH over time is 
uncertain. Methods: 597 patients (pts) with ECG LVH by either Cornell product and/or 
Sokolow-Lyon voltage, enrolled in the LIFE echocardiographic substudy, were examined 
at study baseline and after 1-year of blinded therapy with either Iosartan or atenolol 
based regimens. Echocardiographic LVH was defined by LVMt >116 g/m 2 in men and 
>104 in women. Results: ECG strain was absent at baseline and 1-year (S-/-) in 511 pts, 
present on both ECGs (S+/+) in 47 pts, and was present at baseline but had resolved by 
1-year (S+/-) in 39 pts. At study baseline, compared with S-/- pts, S+/+ and S+/- pts had 
similarly high prevalences of LVH, but the LVH was more severe, with greater LVMI, in 
S+/+ than S+/- pts (p=.038); S-/- pts had significantly lower LVMI and prevalence of LVH. 
After 1-year, S+/+ pts had the greatest LVMI and prevalence of LVH, whereas S+/- pts 
had lower LVMI and prevalence of LVH. (*p<.001 vs baseline) 
Variable Strain-/- Strain+/- Strain+/+ p value 
(n=511) (n=39) (n=47) 
LVMI at baseline (g/m 2) 120±.23 136+25 148+38 <.001 
LVMI at 1 -year (g/m 2) 107_+20* 115¢25" 133_+31 * <.001 
LVH at baseline (%) 66 90 87 <.001 
LVH at 1-year (%) 39* 54* 75 <.001 
Conclusions: In the setting of aggressive antihypertensive therapy and decrease in 
blood pressure, persistence of ECG strain identifies a subgroup of pts with greater l-year 
LVMI and LVH. In contrast, resolution of strain was associated with a marked reduction in 
the risk of LVH at t-year. 
